AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie non-PEO Named Executive Officers Average Summary Compensation Table Total ($) ($)
DEF 14A Proxy Statement Pay vs. Performance Table
Latest, FY2025
12,123,281
Period ended Dec 31, 2025
Change on a year earlier
+7.1%
11,314,957 in FY2024
History
5 years
Since FY2021
Sources
1
Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-PEO Named Executive Officers Average Summary Compensation Table Total ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12,123,281 | +7.1% | Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23) ↗ |
| FY2024 | Dec 31, 2024 | 11,314,957 | -8.2% | Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23) ↗ |
| FY2023 | Dec 31, 2023 | 12,319,311 | +35.0% | Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23) ↗ |
| FY2022 | Dec 31, 2022 | 9,125,252 | -17.3% | Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23) ↗ |
| FY2021 | Dec 31, 2021 | 11,035,630 | – | Proxy Statement (DEF 14A) (abbv-20260508xdef14a.htm, filed 2026-03-23) ↗ |
Cite this data
StockData. (2026). AbbVie Non-PEO Named Executive Officers Average Summary Compensation Table Total ($) ($), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/gov_non_peo_sct
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.